Prophylactic CD45RA-depleted DLI After Haploidentical Transplantation/RIC

Hematologic Malignancy Clinical Trial

Official title:

A Phase I Clinical Trial Assessing Prophylactic Donor CD45RA-depleted Lymphocyte Infusions Into Patients Transplanted With Stem Cell Grafts From Haploidentical Donors After Reduced Intensity Conditioning

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05066412
• Other study ID #: Cd45RA depleted DLI
• Status: Not yet recruiting
• Phase: Phase 1
• Start date: October 15, 2021
• Est. completion date: December 2, 2026

Study information

• Verified date: October 2021
• Source: University Hospital, Geneva
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To assess safety of prophylactic escaladed dose of T naïve depleted (CD45RA depleted donor lymphocyte infusion, in patients with malignant hemopathie who received an allogeneic stem cell transplant from an haplo-identical donor, after a reduced intensity conditionning regiment.

Description:

Primary Objective is to determine whether the administration of prophylactic CD45RAneg (CD45RAneg) memory/effector T lymphocytes is feasible and safe in the early post-transplant period for patients with haploidentical transplant and RIC conditioning.

Donor lymphocytes are isolated from the original donor by non-mobilized mononuclear cell leukapheresis. Repetitive intravenous infusions (up to 3) of escalating doses of CD45RAneg cells, prepared from the leukapheresis by CliniMACS® technology (CD45RA-depletion), storage in vapor nitrogen.

Escalating doses of CD45RAneg cells, for patients with haploidentical graft, intervals of 6-8 weeks, if GvHD is absent starting ≥ 4 weeks from the day of transplantation.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 12
• Est. completion date: December 2, 2026
• Est. primary completion date: June 2, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients who received a stem cell graft from a haploidentical donor after RIC for hematologic malignancies

• Written informed consent of patient and donor obtained

Exclusion Criteria:

• Participant taking Prednisone (or equivalent steroid)

• Participant taking Prednisone (or equivalent steroid)

• Participant taking Mycophenolate Mofetil

• Participant taking Cyclosporine/tacrolimus at therapeutic blood levels

• Progressive hematologic malignancy before transplant

• Second allogeneic transplant

• Acute GvHD = grade 2

• Chronic moderate or severe GvHD (NIH consensus criteria)

• Hematologic or molecular relapse of the primary malignancy requiring chemotherapy or unmanipulated DLI (receiving prophylactic antileukemic agent, eg TKI, is not an exclusion criteria)

• Donor aberrant CD45RA expression due to a polymorphism in CD45 gene

• Participation in another interventional clinical trial within 30 days prior to inclusion

• Pregnant or nursing women. Sexually active women with childbearing potential as well as sexually active male patients who are unwilling to use an effective method of contraception during participation in the study from time of inclusion until 2 months after last dose of CD45RAneg DLI infusion

• Inability to follow the procedures of the study, including, but not limited to, language problems, psychological disorders, dementia

Related Conditions & MeSH terms

• Hematologic Malignancy
• Hematologic Neoplasms

Intervention

Other:
• CD45RAneg cells, prepared from mononuclear cell leukapheresis by CliniMACS® technology
CD45RAneg cells, prepared from mononuclear cell leukapheresis by CliniMACS® technology

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Geneva

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	acute transfusion reaction (CTCAE = 2)	acute transfusion reaction after each DLI infusion (CTCAE = 2)	24 hours after each CD45RA neg DLI infusion
Primary	acute GvHD grade II-IV	acute GvHD grade II-IV measured with MAGIC score	within 8 weeks after each CD45RAneg DLI infusion